Treatment with this compound enhanced degradation of proteins important in neurodegeneration such as tau, TDP43 or ataxin-3 (a polyglutamine expanded protein causing SCA3), and could provide novel strategies for increasing protein degradation by regulating protein degradation by the UPS. The gene discussed is ATXN3; the disease is Machado-Joseph disease.